CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody–associated Vasculitis: 2020 Update

A. Mendel, MD, MSc, C.A. Pineau, MD, Division of Rheumatology, Lupus and Vasculitis Clinic, McGill University, Montréal, Québec; D. Ennis, MD, C. Baldwin, MD, N. Dehghan, MD, N. Dhindsa, MD, Division of Rheumatology, University of British Columbia, Vancouver, British Columbia; E. Go, MD, R.S. Yeung, MD, PhD, Division of Rheumatology, Hospital for Sick Children, University of Toronto, Toronto, Ontario; V. Bakowsky, MD, Division of Rheumatology, QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia; S.M. Benseler, MD, PhD, M. Twilt, MD, PhD, Division of Rheumatology, Department of Pediatrics, Alberta Children’s Hospital, Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Alberta; D.A. Cabral, MBBS, Division of Pediatric Rheumatology, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia; S. Carette, MD, MPhil, C. Pagnoux, MD, MSc, MPH, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; M. Clements-Baker, MD, T.E. Towheed, MD, MS, Division of Rheumatology, Queen’s University, Kingston, Ontario; A.H. Clifford, MD, J.W. Cohen Tervaert, MD, PhD, E. Yacyshyn, MD, Division of Rheumatology, University of Alberta, Edmonton, Alberta; G. Cox, MB, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario; C. Dipchand, MD, MSc, Division of Nephrology, QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia; L. Famorca, MD, S. Garner, MD, MSc, N. Khalidi, MD, Division of Rheumatology, McMaster University, Hamilton, Ontario; A. Fifi-Mah, MD, Division of Rheumatology, University of Calgary, Calgary, Alberta; L.P. Girard, MD, MSc, Division of Nephrology, University of Calgary, Calgary, Alberta; C. Lessard, MD, Centre de Recherche Musculo-Squelettique, Trois-Rivières, Québec; P. Liang, MD, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec; D. Noone, MB, BCh, BAO, MSc, Division of Nephrology, Hospital for Sick Children, University of Toronto, Toronto, Ontario; J.P. Makhzoum, MD, M. Rhéaume, MD, Division of Internal Medicine, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, Québec; N. Milman, MD, MSc, Division of Rheumatology, The Ottawa Hospital, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario; H.N. Reich, MD, PhD, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario; D.B. Robinson, MD, MSc, Section of Rheumatology, University of Manitoba, Winnipeg, Manitoba; D.G. Rumsey, MD, MSc, Division of Pediatric Rheumatology, University of Alberta, Edmonton, Alberta; J. Trudeau, MD, Division of Rheumatology, CISSS Chaudière- Appalaches, Université Laval, Québec City, Québec; L.B. Barra, MD, Division of Rheumatology, Department of Medicine, Western University, London, Ontario, Canada. VB reports advisory board attendance from AbbVie, Eli Lilly, and Janssen, outside the submitted work. AHC reports other fees from AbbVie and personal fees from Roche, outside the submitted work. JWCT reports Chair of the Independent Data Monitoring Committee for InflaRx, outside the submitted work. ND reports personal fees from Novartis, Sandoz, and Amgen, outside the submitted work. SG reports grants from the Vasculitis Foundation and Roche, during the conduct of the submitted work. PL reports grants from Roche, Amgen, Janssen, AbbVie, BMS, and Novartis, outside the submitted work. JT reports personal fees from Roche, personal fees from Medexus, and other fees from Medpace, outside the submitted work. LB reports honoraria from Roche, Bristol Myers Squibb, Boehringer Ingelheim, and Pfizer, outside the submitted work. NK reports personal fees and nonfinancial support from Roche, and nonfinancial support from Bristol Myers Squibb, outside the submitted work. CP reports grants and personal fees from Roche; grants and personal fees from GSK; and personal fees from ChemoCentryx, Sanofi, and InflaRx GmbH, outside the submitted work. The remaining authors have nothing to disclose. Address correspondence to Dr. A. Mendel, Montreal General Hospital, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada. Email: arielle.mendel@mcgill.ca. Accepted for publication September 5, 2020.